US Patent

US11938217 — Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate

Formulation · Assigned to Slayback Pharma LLC · Expires 2038-10-25 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable, ready-to-use injectable pharmaceutical composition that combines neostigmine and glycopyrrolate with a liquid vehicle.

USPTO Abstract

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Drugs covered by this patent

Patent Metadata

Patent number
US11938217
Jurisdiction
US
Classification
Formulation
Expires
2038-10-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Slayback Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.